TOP TIERMARKET NEWSWIRE

News & sentiment

CYTOKINETICS INC (CYTK) — News & AI sentiment

CYTOKINETICS INC (CYTK) news roundup. 1 story in the past week, 21 over 30 days. Average 30-day sentiment is 58.4/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 19 sales totalling $12.0M — net selling of $12.0M. US House Periodic Transaction Reports (90-day window): 1 purchase (~$8K) and 0 sales (~$0). Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

1

avg sentiment 56/100

30d stories

21

avg sentiment 58.4/100

Insider net (90d)

$12.0M

0 buys · 19 sells

Congress (90d)

1

1 buys · 0 sells

CYTK news in the last 24 hours, 7 days, 30 days and 90 days

How much CYTK coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	CYTK stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	1	56/100	CYTK headlines →
Last 30 days	21	58.4/100	CYTK headlines →
Last 90 days	51	56.5/100	CYTK headlines →

Latest stories on CYTK

Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha56 · neutralgeneral

4d ago

Cytokinetics to Participate in September Investor Conferences

GlobeNewswire56 · neutralgeneral

Sep 2

Cytokinetics to Participate in September Investor Conferences

Business Insider56 · neutralgeneral

Sep 2

Truist reiterates Buy on Cytokinetics stock, $112 target on HCM potential

Investing.com Analyst Ratings61 · neutralanalyst

Sep 1

Cytokinetics announces results from ACACIA-HCM, MAPLE-HCM

The Fly55 · neutralproduct/pr

Aug 30

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

StockTitan63 · neutralproduct/pr

Aug 29

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

Barchart63 · neutralproduct/pr

Aug 29

Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript

Seeking Alpha73 · bullishproduct/pr

Aug 28

Cytokinetics heart drug shows promise in trial, but analysts question modest benefits

Reuters58 · neutralproduct/pr

Aug 28

Cytokinetics posts full data from late-stage trial for lead drug in non-obstructive HCM

Seeking Alpha63 · neutralproduct/pr

Aug 28

Cytokinetics Reports Positive Phase 3 Aficamten HCM Results

TipRanks73 · bullishproduct/pr

Aug 28

CYTOKINETICS INC (CYTK) files 8-K

SEC 8-K50 · neutralgeneral

Aug 28

Cytokinetics reports ACACIA-HCM trial met both primary endpoints

The Fly67 · bullishproduct/pr

Aug 28

Cytokinetics Boasts A First-Ever In Heart Disease — And Shares Drop

Investors.com48 · neutralproduct/pr

Aug 28

Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine

StockTitan73 · bullishproduct/pr

Aug 28

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

Yahoo Finance50 · neutralgeneral

Aug 22

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

The Motley Fool50 · neutralgeneral

Aug 22

Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

StockTitan56 · neutralproduct/pr

Aug 20

Cytokinetics Targets Talent Growth with Over 45,000 Equity Awards in August 2026—What Does This Signal for Investors?

MarketChameleon56 · neutralgeneral

Aug 19

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire50 · neutralgeneral

Aug 18

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Insider50 · neutralgeneral

Aug 18

H.C. Wainwright reiterates Cytokinetics stock rating on patent suit

Investing.com Analyst Ratings54 · neutralgeneral

Aug 14

Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript

The Motley Fool56 · neutralearnings

Aug 13

Cytokinetics Files Complaint on Patent Issue Against Bristol-Myers Squibb

MarketWatch38 · neutralgeneral

Aug 13

Cytokinetics sues Bristol-Myers to avoid patent case

Seeking Alpha44 · neutralgeneral

Aug 13

Open CYTK in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →